Atlas Trials

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

Clinical trial NCT03224351 · COMPLETED

Trial details

NCT number
NCT03224351
Sponsor
Vertex Pharmaceuticals Incorporated
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Cystic Fibrosis
Start date
2017-08-08
Primary completion
2018-02-28
Enrollment
124

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.